Synthesis, characterisation and evaluation of benzoxaborole-based hybrids as antiplasmodial agents

dc.contributor.advisorKhanye, Setshaba
dc.contributor.advisorHoppe, Heinrich
dc.contributor.authorGumbo, Maureen
dc.date.accessioned2026-03-09T09:02:15Z
dc.date.issued2017
dc.description.abstractMalaria is a mosquito-borne disease, which continues to pose a threat to the entire humanity. About 40% of the world population is estimated to be at risk of infections by malaria. Despite efforts undertaken by scientific community, government entities and international organizations, malaria is still rampant. The major problem is drug resistance, where the Plasmodium spp have over the past decades developed drug resistance against available drugs. In order to counter this problem, novel antimalarial drugs that are efficacious and with novel mode of action are of great necessity. Benzoxaborole derivatives have been shown to exhibit promising antimalarial activity against Plasmodium falciparum strains. Previous studies reported on the compounds such as 6-(2- (alkoxycarbonyl)pyrazinyl-5-oxy)-1,3-dihydro-1-hydroxy-2,1-benzoxaboroles, which showed good antimalarial activity against both W7 and 3D7 strains without significant toxicity. On the other hand, chloroquine (CQ) and cinnamic acids have a wide variety of biological activity including antimalarial activity. Herein, a hybridisation strategy was employed to synthesise new CQ-benzoxaborole and cinnamoyl-benzoxaborole hybrids. CQ-Benzoxaborole 2.12a-c and cinnamoylbenzoxaborole 2.11a-g hydrid molecules were synthesised in low to good yields. Their structural identities were confirmed using conventional spectroscopic techniques (1H and 13C NMR, and mass spectrometry). CQ-benzoxaborole compounds, however, showed instability, and only 2.12b was used for in vitro biological assay and showed activity comparable to CQ. Furthermore, in vitro biological assay revealed that compounds 2.11a-g poorly inhibited the growth of P. falciparum parasites. Interestingly, these compounds, however, exhibited satisfactory activity against Trypanosoma brucei with IC50 = 0.052 μM for compound 2.11g. The cell cytotoxicity assay of all final compounds confirmed that all CQ-benzoxaborole 2.12b and cinnamoyl-benzoxaborole 2.11a-g hybrids were non-toxic against HeLa cell lines. However, efforts to further expand the structure-activity relationship (SAR) of CQbenzoxaborole by increasing the length of the linker with one extra carbon (Scheme 2.10) were not possible as an important precursor 6-formylbenzoxaborole 2.29 could not be synthesized in sufficient yields.
dc.description.degreeMaster's thesis
dc.description.degreeMSc
dc.format.extent103 pages
dc.identifier.otherhttp://hdl.handle.net/10962/59193
dc.identifier.urihttps://researchrepository.ru.ac.za/handle/123456789/9459
dc.languageEnglish
dc.publisherRhodes University, Faculty of Science, Department of Chemistry
dc.rightsGumbo, Maureen
dc.subjectMalaria -- Chemotherapy
dc.subjectAntimalarials
dc.subjectBoron compounds
dc.subjectDrug resistance
dc.subjectPlasmodium falciparum
dc.subjectDrug development
dc.titleSynthesis, characterisation and evaluation of benzoxaborole-based hybrids as antiplasmodial agents
dc.typeAcademic thesis

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
vital_27456+SOURCE1+SOURCE1.2.pdf
Size:
1.92 MB
Format:
Adobe Portable Document Format